What happens when you take one of the best flow diverters in use today and engineer surface modification?

Enter the new generation of flow diverters and find out, join René CHAPOT (Germany) and Markus MÖHLENBRUCH (Germany) as they introduce the FRED X.

Discover the nature of the surface modification. Learn how FRED X was designed to reduce the rate of thrombose production on the device itself and how, in early clinical experience, it demonstrated similar rates of occlusion to FRED, but with the promise of less thrombogenicity which is associated with older iterations of flow diverters.

Our two experts go on to speak about how the FRED X surface modification allowed for using only mono-aggregation in these initial clinical cases, with Markus MÖHLENBRUCH pointing to the good outcomes obtained with FRED X at 3 to 6 months follow-up, as well as showing an excellent safety profile.

With FRED X, Microvention is poised to enter the next chapter in aneurysm treatment. The early clinical experience discussed here demonstrates a novel device that can be used with mono-aggregation, has had few complications, and holds the potential of being able to be employed in the treatment of both unruptured and ruptured aneurysms.

Join us in this LINNC Paris 2021 with our two experts, and learn more about this novel flow diverter, not just for yourself, but for your patients as well.